Axitinib Labeling Agent with Fluorescent Nanoparticles
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional labeling agents using low-molecular-weight compounds with nitrogen-containing aromatic rings, such as axitinib, face challenges in bioassays due to weak signal intensity and fewer bright spots when binding to target molecules, making it difficult to evaluate their binding properties effectively.
Innovation Solution
A labeling agent is developed where a fluorescent substance-integrated nanoparticle is bound to axitinib via a carbon atom of its nitrogen-containing aromatic ring, enhancing fluorescence intensity and the number of bright spots, thereby improving the evaluation of binding properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Illumination intensity
If conventional labeling agents using low-molecular-weight compounds with nitrogen-containing aromatic rings are used, then the structure is simple and easy to manufacture, but the signal intensity is weak and the number of bright spots is few
Solution Approach 1:
The patent combines axitinib (a low-molecular-weight compound) with fluorescent substance-integrated nanoparticles to create a composite labeling agent. This composite structure integrates the molecular targeting capability of axitinib with the high fluorescence intensity of nanoparticle labels, resolving the contradiction between simple structure and weak signal by merging two different material systems with complementary properties.
Solution Approach 2:
The invention merges the drug molecule axitinib with a fluorescent nanoparticle label through covalent bonding. This combination unifies the targeting function of the drug with the detection function of the fluorescent label, enabling simultaneous molecular targeting and high-intensity fluorescence signaling in a single labeling agent.
2Measurement precision
If conventional labeling agents are used, then the manufacturing process is simple, but the binding property evaluation is difficult due to weak signals
Solution Approach 1:
The patent changes the physical and chemical parameters of the labeling agent by replacing conventional small-molecule fluorescent labels with fluorescent substance-integrated nanoparticles. This parameter change dramatically increases fluorescence intensity and bright spot visibility, enabling precise evaluation of binding properties despite the increased manufacturing complexity.
3Measurement precision
If axitinib is used as a molecular target drug, then the therapeutic specificity is high, but the signal intensity for quantification is insufficient
Solution Approach 1:
The fluorescent nanoparticle acts as an intermediary between axitinib and the detection system. It is covalently bound to axitinib, serving as a signal amplification mediator that converts the weak intrinsic fluorescence of the drug molecule into strong nanoparticle-based fluorescence signals, thereby enabling accurate quantification while preserving the therapeutic specificity of axitinib.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for more accurate quantification and evaluation of molecular target drugs' effects on target molecules in bioassays and histological staining, enabling better assessment of their therapeutic efficacy.
Implementation Method 1
a fluorescent substance-integrated nanoparticle as a label bound thereto
Data Source
AI summary
An object of the present invention is to provide a labeling agent which exhibits excellent binding to a target molecule in a bioassay or histological staining method that relates to a compound containing a nitrogen-containing aromatic ring. The labeling agent according to the present invention is a labeling agent having a structure in which a molecular target drug, which is a compound containing a nitrogen atom-containing aromatic ring, is bound with a label via a divalent linking group, wherein one end of the divalent linking group is bound to a carbon atom of the nitrogen atom-containing aromatic ring. The label is preferably a fluorescent substance-integrated nanoparticle, and the nitrogen atom-containing aromatic ring is preferably a pyridine ring.